Development of immunotherapy against the bone destructive tumor
| Project/Area Number |
23659946
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
HIASA Masahiro 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 助教 (90511337)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 破骨細胞 / 樹状細胞 / TACE / TIMP3 / TIMP-3 |
|---|
| Research Abstract |
Multiple myeloma (MM) generates devastating bone destruction. We recently reported that TNFα converting enzyme (TACE) expression in monocytes cleaved their surface M-CSF receptor (M-CSFR), which drastically disrupts osteoclastogenesis（Blood, 2009）. Because TACE activity is inhibited by TIMP3, we explored the role of BMSC-derived TIMP3 in monocytic differentiation into DC or OC in MM. This study clarified that TIMP3 over-produced in MM bone marrow microenvironment restores surface M-CSFR on monocytes to facilitate their downstream signaling, which causes extensive bone destruction and impaired DC differentiation in MM. TIMP3 may therefore become a novel target in the treatment of MM bone disease.
|
Report
(3 results)
Research Products
(21 results)
-
[Journal Article] Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors2012
Author(s)
Ikegame A, Ozaki S, Tsuji D, Harada T, Fujii S, Nakamura S, Miki H, Nakano A, Kagawa K, Takeuchi K, Abe M, Watanabe K, Hiasa M, Kimura N, Kikuchi Y, Sakamoto A, Habu K, Endo M, Itoh K, Yamada-Okabe H, MatsumotoT
-
Journal Title
Leukemia
Volume: 26
Issue: 9
Pages: 2124-2134
DOI
Related Report
Peer Reviewed
-
[Journal Article] KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts2011
Author(s)
Miki H, Ozaki S, Nakamura S, Oda A, Amou H, Ikegame A, Watanabe K, Hiasa M, Cui Q, Harada T, Fujii S, Nakano A, Kagawa K, Takeuchi K, Yata K, Sakai A, Abe M, Matsumoto T
-
Journal Title
Br J Haematol
Volume: 155
Issue: 3
Pages: 328-339
DOI
Related Report
Peer Reviewed
-
[Journal Article] Delayed treatment with vitamin C and N-acetyl-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib2011
Author(s)
Nakano A, Abe M, Oda A, Amou A, Hiasa M, Nakamura S, Miki H, Harada T, Fujii S, Kagawa K, Takeuchi K, Watanabe T, Ozaki S, Matsumoto T
-
Journal Title
Int J Hematol
Volume: 93
Issue: 6
Pages: 727-735
DOI
Related Report
Peer Reviewed
-
[Journal Article] Targeting myeloma-osteoclast interaction with V γ 9V 6 2 T cells2011
Author(s)
Cui Q, Shibata H, Oda A, Amou H, Nakano A, Yata K, Hiasa M, Watanabe K, Nakamura S, Miki H, Harada T, Fujii S, Kagawa K, Takeuchi K, Ozaki S, Matsumoto T, Abe M
-
Journal Title
Int J Hematol
Volume: 94
Issue: 1
Pages: 63-70
DOI
Related Report
Peer Reviewed
-
[Journal Article] The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells2011
Author(s)
Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K, Miki H, Nakamura S, Harada T, Fujii S, Kagawa K, Endo I, Yata K, Sakai A, Ozaki S, Matsumoto T, Abe M
-
Journal Title
Leukemia
Volume: 25
Issue: 7
Pages: 1182-1188
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
